Project Grant R16AI201140
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $188K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Jamaica, NY 11439, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $233,125 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate a toolkit for studying 1-deoxy-D-xylulose 5-phosphate synthase (DXPS) as a driver of metabolic adaptation in bacterial pathogens. The research targets bacterial central metabolism as a route to novel antibacterial strategies, focusing on how pathogens remodel their metabolism to...
- The National Institute of Allergy and Infectious Diseases awarded the Research Foundation of The City University of New York $142,237 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the molecular mechanisms of E. coli sibling inhibition and evaluate the bioactive potential of the E. coli sibling inhibitor compound. The research examines a novel form of intra-species bacterial competition whereby genetically identical E. coli cells...
- The National Institute of Allergy and Infectious Diseases awarded New York University $254,250 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to test the epigenetic basis and evolutionary generality of bacterial persistence in Staphylococcus aureus. The research examines how bacteria survive antibiotic treatment without genetic changes—a phenomenon distinct from drug resistance and drug tolerance. The project builds on preliminary findings that...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...
- The National Institute of Allergy and Infectious Diseases awarded New York University $508,500 on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research investigating how myeloid cells, particularly neutrophils, regulate plasma membrane homeostasis to control decisions between functional immune programs including migration, phagocytosis, and netosis. The research, conducted as a postdoctoral project at New York University School of Medicine...
- The National Institute of Allergy and Infectious Diseases awarded The Rockefeller University $798,670 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop bioinformatics-guided methods for discovering novel antibiotics from previously inaccessible microbial sources. The project couples direct nanopore metagenomic sequencing with synthetic bioinformatic natural products discovery methods to identify complete biosynthetic gene clusters from...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $195,640 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research integrating genomic and clinical approaches to define and prevent cefiderocol resistance in carbapenem-resistant organisms. The research addresses gaps in understanding cefiderocol resistance mechanisms and clinical use in carbapenem-resistant organisms, which cause severe...
- The National Institute of Allergy and Infectious Diseases awarded New York University $742,364 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate autolysin control pathways in Pseudomonas aeruginosa. The research examines how bacteria regulate cell wall-degrading enzymes (autolysins) to control their activity during cell growth and division. Pseudomonas aeruginosa serves as the model organism because it causes serious human infections...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $537,619 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Central Florida Board of Trustees. The grant, awarded on March 1, 2025, will support the development of a single biosensor platform for the simultaneous detection of HIV, hepatitis B, and hepatitis C viruses, particularly in resource-limited settings. The project aims to integrate the university's recently...